Physician profile
William David James
NPI 1851754865
$3,374.78
in general payments reported to CMS, 2019-2025
27 companies · $935 in 2025
The $935 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.89 · 2022: $627 · 2023: $533 · 2024: $1,184 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,652.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.80 | 2021-2025 | |
| Novo Nordisk INC | $311.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $234.83 | 2022-2025 | Farxiga, Airsupra |
| Amgen INC. | $206.54 | 2022-2025 | Evenity, Prolia, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.65 | 2024-2025 | Caplyta |
| Pfizer INC. | $183.00 | 2021-2025 | |
| Glaxosmithkline, LLC. | $159.09 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $135.40 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $124.42 | 2022-2025 | |
| Astellas Pharma US INC | $92.18 | 2022-2025 | Veozah |
| Indivior INC. | $90.14 | 2024-2025 | Sublocade |
| Alkermes, INC. | $85.30 | 2022-2024 | Aristada, Vivitrol, Lybalvi |
| Dexcom, INC. | $75.32 | 2022-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $73.31 | 2022-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $66.22 | 2022-2025 | Eliquis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $60.78 | 2024 | Thinprep 2000 Processor, Aptima |
| Lilly USA, LLC | $57.31 | 2022-2024 | Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $51.19 | 2022-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $32.95 | 2023 | Gardasil 9, Proquad, Vaxelis |
| Organon LLC | $27.40 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $22.39 | 2022 | |
| Axsome Therapeutics, INC. | $16.19 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $16.02 | 2025 | Inspire |
| Baxter Healthcare | $15.29 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $14.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.26 | 2025 | Zoryve |
| Boston Scientific Corporation | $12.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.